Virtual Library
Start Your Search
C. Lund
Author of
-
+
MINI 18 - Radiation Topics in Localized NSCLC (ID 139)
- Event: WCLC 2015
- Type: Mini Oral
- Track: Treatment of Localized Disease - NSCLC
- Presentations: 1
-
+
MINI18.09 - Survival of Elderly Patients after SABR for Early Lung Cancers - A Population Based Retrospective Comparison of Survival among Age Cohorts (ID 3113)
16:45 - 18:15 | Author(s): C. Lund
- Abstract
- Presentation
Background:
As Stereotactic Ablative Body Radiotherapy (SABR) is increasingly used to treat early non-small cell lung cancer, a larger proportion of elderly patients are now receiving radical therapy. This review aims to assess whether age significantly influences overall survival (OS) in patients with early stage lung cancer treated by SABR according to a standard provincial protocol, and to determine if a maximum age guideline should be introduced.
Methods:
Using a population database all lung-SABR patients were divided into age categories <70 yo (n=45), 70-74 (n=28). 75-79 (n=39),80-84 (n=33) and ≥85 (n=22). Patient and tumor characteristics were collected including: sex, Charlson comorbidity index (CCI), ECOG performance status, tumor diameter, maximum tumor SUV (SUVmax), forced expiratory volume in 1 second (FEV1), and whether a pathologic diagnosis was obtained. For each cohort, OS from date of SABR was calculated. Variability among tumor characteristics between cohorts was evaluated by Chi-squared test and OS was calculated by Kaplan-Meier.
Results:
185 patients were treated from 2009 to 2013. Median age was 76 (range 49-94). The percentage of patients with pathologic diagnoses and the percentage of males was similar among age categories. FEV1 values, ECOG status, SUVmax values and tumor length were not significantly different among the age categories. Older patients had significantly greater CCI scores (see table p=0.001). Median OS for all patients was 36 months and was not reduced in the oldest cohorts (<70: 34 months, 70-74: 24 months: 75-80: 39 months, 80-84:36 months, ≥85: 36 months).Age Categories (years old) <70 70-74 75-79 80-84 85+ CCI 0-1 5 (%) 0 0 0 0 2-4 59 (%) 39 35 15 10 5-7 34 (%) 54 57 76 60 8 or more 2 (%) 7 8 9 30
Conclusion:
Based on 5 years of population based data, an age cutoff for lung-SABR is not endorsed. In our treated population, patients ≥85 yo have similar OS as younger patients despite greater CCI scores.
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
